Curanex Pharmaceuticals Regains Nasdaq Minimum Bid Price Compliance

Curanex Pharmaceuticals Inc. has announced it has regained compliance with Nasdaq's minimum bid price rule. The company's common stock maintained a closing bid price of at least $1.00 per share for ten consecutive business days, from August 20 to September 2, 2026. This action resolves a previous delisting matter, ensuring the company's continued listing on the exchange.